GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Gross Margin %

Samsung BioLogics Co (XKRX:207940) Gross Margin % : 53.23% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Samsung BioLogics Co's Gross Profit for the three months ended in Dec. 2024 was ₩668,750 Mil. Samsung BioLogics Co's Revenue for the three months ended in Dec. 2024 was ₩1,256,439 Mil. Therefore, Samsung BioLogics Co's Gross Margin % for the quarter that ended in Dec. 2024 was 53.23%.


The historical rank and industry rank for Samsung BioLogics Co's Gross Margin % or its related term are showing as below:

XKRX:207940' s Gross Margin % Range Over the Past 10 Years
Min: -25.75   Med: 32.05   Max: 50.38
Current: 50.38


During the past 11 years, the highest Gross Margin % of Samsung BioLogics Co was 50.38%. The lowest was -25.75%. And the median was 32.05%.

XKRX:207940's Gross Margin % is ranked worse than
60.46% of 741 companies
in the Biotechnology industry
Industry Median: 60.19 vs XKRX:207940: 50.38

Samsung BioLogics Co had a gross margin of 53.23% for the quarter that ended in Dec. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Samsung BioLogics Co was 12.20% per year.


Samsung BioLogics Co Gross Margin % Historical Data

The historical data trend for Samsung BioLogics Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Gross Margin % Chart

Samsung BioLogics Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.72 46.33 48.93 48.79 50.38

Samsung BioLogics Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.49 44.37 56.86 45.84 53.23

Competitive Comparison of Samsung BioLogics Co's Gross Margin %

For the Biotechnology subindustry, Samsung BioLogics Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's Gross Margin % falls into.


;
;

Samsung BioLogics Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Samsung BioLogics Co's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=2290844.6 / 4547322.176
=(Revenue - Cost of Goods Sold) / Revenue
=(4547322.176 - 2256477.586) / 4547322.176
=50.38 %

Samsung BioLogics Co's Gross Margin for the quarter that ended in Dec. 2024 is calculated as


Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=668749.6 / 1256439.192
=(Revenue - Cost of Goods Sold) / Revenue
=(1256439.192 - 587689.626) / 1256439.192
=53.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Samsung BioLogics Co  (XKRX:207940) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Samsung BioLogics Co had a gross margin of 53.23% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Samsung BioLogics Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines